Intrinsic value of Repligen - RGEN

Previous Close

$48.79

  Intrinsic Value

$0.79

stock screener

  Rating & Target

str. sell

-98%

Previous close

$48.79

 
Intrinsic value

$0.79

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of RGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  35.10
  32.09
  29.38
  26.94
  24.75
  22.77
  21.00
  19.40
  17.96
  16.66
  15.50
  14.45
  13.50
  12.65
  11.89
  11.20
  10.58
  10.02
  9.52
  9.07
  8.66
  8.29
  7.96
  7.67
  7.40
  7.16
  6.94
  6.75
  6.58
  6.42
Revenue, $m
  190
  252
  326
  413
  516
  633
  766
  914
  1,079
  1,258
  1,453
  1,663
  1,888
  2,127
  2,379
  2,646
  2,926
  3,219
  3,525
  3,845
  4,178
  4,524
  4,884
  5,259
  5,648
  6,053
  6,473
  6,910
  7,364
  7,837
Variable operating expenses, $m
  138
  168
  203
  245
  294
  351
  414
  485
  564
  650
  696
  797
  905
  1,019
  1,140
  1,268
  1,402
  1,543
  1,689
  1,843
  2,002
  2,168
  2,341
  2,520
  2,707
  2,901
  3,102
  3,312
  3,529
  3,756
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  138
  168
  203
  245
  294
  351
  414
  485
  564
  650
  696
  797
  905
  1,019
  1,140
  1,268
  1,402
  1,543
  1,689
  1,843
  2,002
  2,168
  2,341
  2,520
  2,707
  2,901
  3,102
  3,312
  3,529
  3,756
Operating income, $m
  52
  84
  122
  168
  221
  282
  352
  429
  514
  608
  757
  866
  983
  1,107
  1,239
  1,378
  1,524
  1,676
  1,836
  2,002
  2,176
  2,356
  2,544
  2,739
  2,941
  3,152
  3,371
  3,598
  3,835
  4,081
EBITDA, $m
  140
  184
  239
  303
  378
  464
  561
  670
  790
  922
  1,065
  1,219
  1,383
  1,558
  1,743
  1,939
  2,144
  2,359
  2,583
  2,817
  3,061
  3,315
  3,579
  3,853
  4,139
  4,435
  4,743
  5,063
  5,396
  5,742
Interest expense (income), $m
  0
  7
  10
  14
  20
  26
  33
  41
  51
  61
  73
  86
  100
  115
  131
  148
  166
  184
  204
  225
  247
  270
  293
  318
  343
  370
  398
  426
  456
  487
  520
Earnings before tax, $m
  45
  74
  108
  148
  195
  249
  310
  378
  453
  535
  671
  766
  868
  977
  1,091
  1,212
  1,339
  1,472
  1,611
  1,755
  1,906
  2,063
  2,226
  2,395
  2,571
  2,754
  2,944
  3,142
  3,348
  3,562
Tax expense, $m
  12
  20
  29
  40
  53
  67
  84
  102
  122
  144
  181
  207
  234
  264
  295
  327
  362
  397
  435
  474
  515
  557
  601
  647
  694
  744
  795
  848
  904
  962
Net income, $m
  33
  54
  79
  108
  143
  182
  226
  276
  331
  390
  490
  559
  634
  713
  797
  885
  978
  1,074
  1,176
  1,281
  1,391
  1,506
  1,625
  1,748
  1,877
  2,011
  2,149
  2,294
  2,444
  2,600

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  804
  1,062
  1,374
  1,744
  2,175
  2,671
  3,231
  3,858
  4,551
  5,309
  6,132
  7,018
  7,965
  8,973
  10,039
  11,164
  12,344
  13,581
  14,874
  16,222
  17,627
  19,089
  20,609
  22,190
  23,832
  25,538
  27,312
  29,156
  31,073
  33,067
Adjusted assets (=assets-cash), $m
  804
  1,062
  1,374
  1,744
  2,175
  2,671
  3,231
  3,858
  4,551
  5,309
  6,132
  7,018
  7,965
  8,973
  10,039
  11,164
  12,344
  13,581
  14,874
  16,222
  17,627
  19,089
  20,609
  22,190
  23,832
  25,538
  27,312
  29,156
  31,073
  33,067
Revenue / Adjusted assets
  0.236
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
  0.237
Average production assets, $m
  404
  533
  690
  876
  1,093
  1,342
  1,624
  1,938
  2,287
  2,668
  3,081
  3,526
  4,002
  4,508
  5,044
  5,609
  6,202
  6,824
  7,473
  8,151
  8,857
  9,591
  10,355
  11,149
  11,974
  12,831
  13,723
  14,649
  15,612
  16,614
Working capital, $m
  43
  57
  73
  93
  116
  142
  172
  206
  243
  283
  327
  374
  425
  478
  535
  595
  658
  724
  793
  865
  940
  1,018
  1,099
  1,183
  1,271
  1,362
  1,456
  1,555
  1,657
  1,763
Total debt, $m
  153
  218
  298
  392
  502
  629
  772
  932
  1,108
  1,302
  1,511
  1,737
  1,979
  2,236
  2,508
  2,794
  3,096
  3,411
  3,741
  4,084
  4,443
  4,815
  5,203
  5,606
  6,025
  6,460
  6,912
  7,382
  7,871
  8,380
Total liabilities, $m
  205
  271
  350
  445
  555
  681
  824
  984
  1,161
  1,354
  1,564
  1,790
  2,031
  2,288
  2,560
  2,847
  3,148
  3,463
  3,793
  4,137
  4,495
  4,868
  5,255
  5,658
  6,077
  6,512
  6,965
  7,435
  7,924
  8,432
Total equity, $m
  599
  791
  1,023
  1,299
  1,621
  1,990
  2,407
  2,874
  3,390
  3,955
  4,568
  5,228
  5,934
  6,685
  7,479
  8,317
  9,197
  10,118
  11,081
  12,086
  13,132
  14,221
  15,354
  16,531
  17,755
  19,026
  20,347
  21,721
  23,149
  24,635
Total liabilities and equity, $m
  804
  1,062
  1,373
  1,744
  2,176
  2,671
  3,231
  3,858
  4,551
  5,309
  6,132
  7,018
  7,965
  8,973
  10,039
  11,164
  12,345
  13,581
  14,874
  16,223
  17,627
  19,089
  20,609
  22,189
  23,832
  25,538
  27,312
  29,156
  31,073
  33,067
Debt-to-equity ratio
  0.250
  0.280
  0.290
  0.300
  0.310
  0.320
  0.320
  0.320
  0.330
  0.330
  0.330
  0.330
  0.330
  0.330
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
  0.340
Adjusted equity ratio
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745
  0.745

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  33
  54
  79
  108
  143
  182
  226
  276
  331
  390
  490
  559
  634
  713
  797
  885
  978
  1,074
  1,176
  1,281
  1,391
  1,506
  1,625
  1,748
  1,877
  2,011
  2,149
  2,294
  2,444
  2,600
Depreciation, amort., depletion, $m
  88
  101
  116
  135
  156
  181
  210
  241
  276
  314
  308
  353
  400
  451
  504
  561
  620
  682
  747
  815
  886
  959
  1,035
  1,115
  1,197
  1,283
  1,372
  1,465
  1,561
  1,661
Funds from operations, $m
  121
  154
  195
  243
  299
  363
  436
  517
  607
  704
  798
  912
  1,034
  1,164
  1,301
  1,446
  1,598
  1,757
  1,923
  2,096
  2,277
  2,465
  2,660
  2,863
  3,074
  3,294
  3,522
  3,759
  4,005
  4,261
Change in working capital, $m
  11
  14
  17
  20
  23
  26
  30
  33
  37
  40
  44
  47
  51
  54
  57
  60
  63
  66
  69
  72
  75
  78
  81
  84
  88
  91
  95
  98
  102
  106
Cash from operations, $m
  110
  141
  178
  223
  276
  337
  406
  484
  570
  664
  754
  865
  984
  1,110
  1,244
  1,386
  1,535
  1,691
  1,854
  2,025
  2,202
  2,387
  2,579
  2,779
  2,987
  3,203
  3,427
  3,660
  3,903
  4,155
Maintenance CAPEX, $m
  -30
  -40
  -53
  -69
  -88
  -109
  -134
  -162
  -194
  -229
  -267
  -308
  -353
  -400
  -451
  -504
  -561
  -620
  -682
  -747
  -815
  -886
  -959
  -1,035
  -1,115
  -1,197
  -1,283
  -1,372
  -1,465
  -1,561
New CAPEX, $m
  -104
  -130
  -157
  -186
  -217
  -249
  -282
  -315
  -348
  -381
  -413
  -445
  -476
  -506
  -536
  -565
  -593
  -621
  -649
  -678
  -706
  -735
  -764
  -794
  -825
  -857
  -891
  -926
  -963
  -1,002
Cash from investing activities, $m
  -134
  -170
  -210
  -255
  -305
  -358
  -416
  -477
  -542
  -610
  -680
  -753
  -829
  -906
  -987
  -1,069
  -1,154
  -1,241
  -1,331
  -1,425
  -1,521
  -1,621
  -1,723
  -1,829
  -1,940
  -2,054
  -2,174
  -2,298
  -2,428
  -2,563
Free cash flow, $m
  -25
  -29
  -32
  -32
  -28
  -21
  -10
  6
  28
  54
  74
  112
  155
  204
  258
  317
  381
  449
  522
  600
  681
  767
  856
  950
  1,047
  1,148
  1,253
  1,362
  1,475
  1,592
Issuance/(repayment) of debt, $m
  53
  66
  80
  94
  110
  126
  143
  160
  177
  193
  210
  226
  242
  257
  272
  287
  301
  315
  330
  344
  358
  373
  388
  403
  419
  435
  452
  470
  489
  509
Issuance/(repurchase) of shares, $m
  122
  138
  154
  167
  179
  187
  191
  191
  185
  174
  123
  100
  72
  38
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  175
  204
  234
  261
  289
  313
  334
  351
  362
  367
  333
  326
  314
  295
  272
  287
  301
  315
  330
  344
  358
  373
  388
  403
  419
  435
  452
  470
  489
  509
Total cash flow (excl. dividends), $m
  150
  175
  201
  230
  261
  292
  324
  357
  390
  422
  407
  438
  469
  498
  530
  603
  682
  765
  852
  944
  1,039
  1,140
  1,244
  1,353
  1,466
  1,583
  1,705
  1,832
  1,964
  2,100
Retained Cash Flow (-), $m
  -155
  -192
  -232
  -276
  -322
  -369
  -418
  -467
  -516
  -565
  -613
  -660
  -706
  -751
  -795
  -837
  -880
  -921
  -963
  -1,005
  -1,047
  -1,089
  -1,133
  -1,177
  -1,223
  -1,271
  -1,321
  -1,374
  -1,428
  -1,486
Prev. year cash balance distribution, $m
  149
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  7
  9
  12
  16
  20
  25
  30
  37
  44
  52
  60
  70
  80
  91
  102
  114
  127
  140
  154
  169
  185
  201
  217
  234
  252
  271
  291
  311
  332
  353
Cash available for distribution, $m
  144
  -17
  -31
  -46
  -61
  -77
  -93
  -110
  -126
  -143
  -206
  -222
  -237
  -252
  -265
  -234
  -198
  -157
  -111
  -61
  -7
  50
  111
  175
  242
  312
  384
  458
  535
  615
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  138
  -16
  -27
  -37
  -47
  -56
  -63
  -69
  -73
  -75
  -98
  -95
  -90
  -85
  -78
  -60
  -43
  -29
  -17
  -8
  -1
  4
  7
  9
  9
  9
  8
  7
  6
  5
Current shareholders' claim on cash, %
  91.9
  85.6
  80.6
  76.6
  73.4
  70.8
  68.7
  67.0
  65.6
  64.5
  63.9
  63.5
  63.2
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1
  63.1

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

FINANCIAL RATIOS  of  Repligen (RGEN)

Valuation Ratios
P/E Ratio 137.6
Price to Sales 15.7
Price to Book 9.8
Price to Tangible Book
Price to Cash Flow 206.4
Price to Free Cash Flow 412.8
Growth Rates
Sales Growth Rate 25%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 33.3%
Cap. Spend. - 3 Yr. Gr. Rate -4.4%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 56.2%
Total Debt to Equity 56.2%
Interest Coverage 0
Management Effectiveness
Return On Assets 5.5%
Ret/ On Assets - 3 Yr. Avg. 6.2%
Return On Total Capital 6.2%
Ret/ On T. Cap. - 3 Yr. Avg. 7.1%
Return On Equity 8.2%
Return On Equity - 3 Yr. Avg. 7.8%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 54.3%
Gross Margin - 3 Yr. Avg. 55.9%
EBITDA Margin 16.2%
EBITDA Margin - 3 Yr. Avg. 20.4%
Operating Margin 15.2%
Oper. Margin - 3 Yr. Avg. 16.4%
Pre-Tax Margin 11.4%
Pre-Tax Margin - 3 Yr. Avg. 14.7%
Net Profit Margin 11.4%
Net Profit Margin - 3 Yr. Avg. 11.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 19.3%
Payout Ratio 0%

RGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RGEN stock intrinsic value calculation we used $141 million for the last fiscal year's total revenue generated by Repligen. The default revenue input number comes from 2017 income statement of Repligen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RGEN stock valuation model: a) initial revenue growth rate of 35.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for RGEN is calculated based on our internal credit rating of Repligen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Repligen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RGEN stock the variable cost ratio is equal to 81.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for RGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6.6% for Repligen.

Corporate tax rate of 27% is the nominal tax rate for Repligen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RGEN stock is equal to 4.8%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RGEN are equal to 212%.

Life of production assets of 10 years is the average useful life of capital assets used in Repligen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RGEN is equal to 22.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $592 million for Repligen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 38 million for Repligen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Repligen at the current share price and the inputted number of shares is $1.9 billion.

RELATED COMPANIES Price Int.Val. Rating
TECH Bio-Techne 156.42 68.51  str.sell
BMRN BioMarin Pharm 101.90 3.01  str.sell
TMO Thermo Fisher 216.85 95.38  str.sell

COMPANY NEWS

▶ Repligen to Report Second Quarter 2018 Financial Results   [Jul-19-18 11:48AM  GlobeNewswire]
▶ CVS will offer home delivery of prescriptions   [Jun-19-18 01:25PM  Yahoo Finance Video]
▶ Moving Average Crossover Alert: Repligen (RGEN)   [May-23-18 07:34AM  Zacks]
▶ Repligen: 1Q Earnings Snapshot   [May-08-18 07:59AM  Associated Press]
▶ Repligen to Report First Quarter 2018 Financial Results   [Apr-30-18 11:00AM  GlobeNewswire]
▶ 3 Top Growth Stocks to Buy Right Now   [Apr-26-18 10:50AM  Motley Fool]
▶ 3 Top Stocks You Can Buy and Hold for the Next Decade   [Apr-24-18 07:47AM  Motley Fool]
▶ My Investing Horror Story: Selling Too Early   [Apr-12-18 06:33AM  Motley Fool]
▶ Repligen beats Street 4Q forecasts   [Feb-22-18 08:43AM  Associated Press]
▶ 3 Growth Stocks to Buy for 2018   [Dec-20-17 06:34AM  Motley Fool]
▶ Top 3 Healthcare Penny Stocks for 2017   [Dec-10-17 03:59PM  Investopedia]
▶ 3 Growth Stocks to Buy and Hold for 25 Years   [Dec-07-17 09:00AM  Motley Fool]
▶ 3 Bioeconomy Stocks That Have a Killer Advantage   [Nov-29-17 09:16AM  Motley Fool]
▶ Repligen tops Street 3Q forecasts   [07:43AM  Associated Press]
▶ Top 3 Healthcare Penny Stocks for 2017   [Nov-08-17 12:20PM  Investopedia]
▶ ETFs with exposure to Repligen Corp. : November 1, 2017   [Nov-01-17 12:36PM  Capital Cube]
▶ Stocks With Rising Relative Strength: Repligen   [Oct-31-17 03:00AM  Investor's Business Daily]
▶ ETFs with exposure to Repligen Corp. : October 20, 2017   [Oct-20-17 10:24AM  Capital Cube]
▶ ETFs with exposure to Repligen Corp. : October 9, 2017   [Oct-09-17 11:59AM  Capital Cube]
▶ ETFs with exposure to Repligen Corp. : September 28, 2017   [Sep-28-17 10:19AM  Capital Cube]
▶ Repligen Announces Analyst Day and Webcast   [Sep-15-17 07:30AM  GlobeNewswire]
▶ Repligen beats Street 2Q forecasts   [Aug-03-17 06:26PM  Associated Press]
▶ Repligen beats Street 2Q forecasts   [10:43AM  Associated Press]
▶ Repligen to Report Second Quarter 2017 Financial Results   [Jul-27-17 07:00AM  GlobeNewswire]
▶ Top Ranked Momentum Stocks to Buy for July 3rd   [Jul-03-17 11:30AM  Zacks]
▶ ETFs with exposure to Repligen Corp. : June 19, 2017   [Jun-19-17 04:03PM  Capital Cube]
▶ Repligen tops Street 1Q forecasts   [May-04-17 07:53AM  Associated Press]
▶ ETFs with exposure to Repligen Corp. : May 1, 2017   [May-01-17 04:21PM  Capital Cube]
▶ ETFs with exposure to Repligen Corp. : April 21, 2017   [Apr-21-17 03:04PM  Capital Cube]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.